{"meta":{"query_hash":"a66805de879b","filters":{"venue":"Leukemia Research Reports"},"cohort_total":8,"direct_labels_cover":0,"predictions_cover":8,"exported":8,"export_cap":100000,"truncated":false,"label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12"},"permalink":"https://metacan.xera.ac/q/a66805de879b","api":"https://metacan.xera.ac/api/v1/cohort?venue=Leukemia+Research+Reports"},"results":[{"id":"W2057466968","doi":"10.1016/j.lrr.2014.06.003","title":"An exploratory phase 2 study of investigational Aurora A kinase inhibitor alisertib (MLN8237) in acute myelogenous leukemia and myelodysplastic syndromes","year":2014,"lang":"en","type":"article","venue":"Leukemia Research Reports","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":79,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Maisonneuve-Rosemont","funders":"Takeda Oncology","keywords":"Medicine; Nausea; Neutropenia; Internal medicine; Adverse effect; Febrile neutropenia; Leukemia; Myeloid leukemia; Myelodysplastic syndromes; Oncology; Gastroenterology; Bone marrow; Toxicity","score_opus":0.05372415204847806,"score_gpt":0.37175913493930307,"score_spread":0.318034982890825,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2057466968","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9959601,0.00022817384,0.000049428163,0.00027314163,0.00015028148,0.0026881776,0.00001993672,0.0001303502,0.00050041266],"genre_scores_gemma":[0.9973213,0.00009273713,0.0008470344,0.00014117146,0.0003015765,0.0005639837,0.00013561844,0.00014100807,0.0004555616],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.98966104,0.0016311032,0.0017216825,0.0016282736,0.0038691182,0.0014888],"domain_scores_gemma":[0.99367696,0.00092713285,0.00039705264,0.0019321358,0.0016051849,0.0014615073],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00812272,0.00055393716,0.001237659,0.0020409995,0.00035590606,0.00013647237,0.00045095955,0.00043115354,0.00009101852],"category_scores_gemma":[0.0045458796,0.0005102754,0.00011384819,0.0020988418,0.0011805425,0.00070712966,0.00055959396,0.0021854043,0.00003305721],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.007552709,0.008603104,0.2062881,0.0020337175,0.001208615,0.09160518,0.026774243,0.00096958457,0.6179872,0.0006759934,0.008936165,0.027365394],"study_design_scores_gemma":[0.1139438,0.092629015,0.45467487,0.0040731216,0.0013910612,0.02609582,0.03485307,0.09113041,0.15805379,0.008848611,0.009468028,0.0048384136],"about_ca_topic_score_codex":0.001846277,"about_ca_topic_score_gemma":0.0007210056,"teacher_disagreement_score":0.4599334,"about_ca_system_score_codex":0.0051317024,"about_ca_system_score_gemma":0.008789045,"threshold_uncertainty_score":0.9997349},"labels":[],"label_agreement":null},{"id":"W2120357152","doi":"10.1016/j.lrr.2013.12.001","title":"Relationship between baseline white blood cell count and renal and hepatic function in older patients with acute myeloid leukemia","year":2014,"lang":"en","type":"article","venue":"Leukemia Research Reports","topic":"Inflammatory Biomarkers in Disease Prognosis","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research; Princess Margaret Cancer Centre","funders":"Eisai; Yuhan; National Comprehensive Cancer Network; Teva Pharmaceutical Industries","keywords":"Medicine; Creatinine; White blood cell; Internal medicine; Decitabine; Renal function; Cytarabine; Myeloid leukemia; Gastroenterology; Myeloid","score_opus":0.01774550426879862,"score_gpt":0.27612538088007427,"score_spread":0.25837987661127565,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2120357152","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9967075,0.00016927677,0.00018986354,0.00016572954,0.00004669085,0.0012008843,0.000010565644,0.00006079417,0.0014486978],"genre_scores_gemma":[0.9978486,0.000028896879,0.0009698862,0.00008288246,0.0001449443,0.00015369554,0.00020593713,0.000053668544,0.0005115452],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9960237,0.00044512015,0.0006736571,0.00073638733,0.001533435,0.0005876879],"domain_scores_gemma":[0.9974374,0.0006191044,0.00022355883,0.00062430574,0.00064098823,0.00045464456],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0040697833,0.00025556845,0.00039409698,0.00053054036,0.00024489872,0.000081397855,0.00006717312,0.00023544305,0.00003877524],"category_scores_gemma":[0.001246831,0.0002118946,0.000042641583,0.00057169766,0.0003125868,0.00024669082,0.00014060955,0.0007852741,0.000007376281],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006275276,0.00008835631,0.9955428,0.00041140284,0.00008239167,0.0006502498,0.00014285337,0.000005334611,0.00019972857,0.00001244095,0.0009150569,0.0013218081],"study_design_scores_gemma":[0.0040106303,0.00053821347,0.9923858,0.00037631625,0.0003545044,0.00010338156,0.000033483444,0.00051294285,0.0005836608,0.0003192264,0.0005590169,0.00022284436],"about_ca_topic_score_codex":0.00013881354,"about_ca_topic_score_gemma":0.00006652614,"teacher_disagreement_score":0.0033831026,"about_ca_system_score_codex":0.0010071868,"about_ca_system_score_gemma":0.0010270562,"threshold_uncertainty_score":0.8640811},"labels":[],"label_agreement":null},{"id":"W2168088054","doi":"10.1016/j.lrr.2015.07.003","title":"A radiolabeled antibody targeting CD123+ leukemia stem cells – initial radioimmunotherapy studies in NOD/SCID mice engrafted with primary human AML","year":2015,"lang":"en","type":"article","venue":"Leukemia Research Reports","topic":"Radiopharmaceutical Chemistry and Applications","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Hospital for Sick Children; University Health Network; Ontario Institute for Cancer Research; University of Toronto","funders":"Canadian Institutes of Health Research; CSL Limited","keywords":"Radioimmunotherapy; Interleukin-3 receptor; Nod; Medicine; Cancer research; Leukemia; Bone marrow; Stem cell; Monoclonal antibody; Spleen; Immunology; Antibody; Biology; Endocrinology; Cell biology","score_opus":0.1673720073511262,"score_gpt":0.463160429935388,"score_spread":0.29578842258426175,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2168088054","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98860455,0.003988594,0.000040217714,0.00036741619,0.00010333901,0.0014334825,0.0000071603695,0.00016923895,0.0052860095],"genre_scores_gemma":[0.9949547,0.00042703815,0.0010676652,0.0002463338,0.0005163814,0.00035048363,0.00018078004,0.000087652166,0.002168973],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99477255,0.00036051963,0.0010323299,0.0009459453,0.0018180379,0.0010705913],"domain_scores_gemma":[0.9966109,0.0004120141,0.00026412265,0.00088552764,0.0012031305,0.00062432984],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0043818057,0.00038770106,0.0008600538,0.00031264362,0.00035014824,0.0000800403,0.00025933603,0.00025144967,0.00004940154],"category_scores_gemma":[0.0003405675,0.00031859014,0.00010262377,0.0012917855,0.000829964,0.00021199317,0.00014863402,0.0017980296,0.00003487725],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010541674,0.00024771286,0.0045024944,0.0005408942,0.0002721892,0.009116442,0.0013902474,0.00012371823,0.9730444,0.000034048557,0.008946453,0.0007272302],"study_design_scores_gemma":[0.012092978,0.0009866281,0.001994159,0.0011244603,0.00014406319,0.0037970857,0.0032084717,0.0008369584,0.9252542,0.00029764522,0.04936232,0.0009010143],"about_ca_topic_score_codex":0.0003264419,"about_ca_topic_score_gemma":0.000014004204,"teacher_disagreement_score":0.047790185,"about_ca_system_score_codex":0.006247604,"about_ca_system_score_gemma":0.0035053187,"threshold_uncertainty_score":0.9999266},"labels":[],"label_agreement":null},{"id":"W4283744241","doi":"10.1016/j.lrr.2022.100335","title":"The mosaic puzzle of the therapeutic monoclonal antibodies and antibody fragments - A modular transition from full-length immunoglobulins to antibody mimetics","year":2022,"lang":"en","type":"article","venue":"Leukemia Research Reports","topic":"Monoclonal and Polyclonal Antibodies Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Monoclonal antibody; Antibody; Immunogenicity; Hybridoma technology; Computational biology; Molecular biology; Biology; Immunology","score_opus":0.034008251335591856,"score_gpt":0.3611706860590909,"score_spread":0.32716243472349904,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4283744241","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9822527,0.00684468,0.00011852966,0.007854,0.00033095776,0.001601067,0.00022687887,0.000034212484,0.00073697756],"genre_scores_gemma":[0.99518853,0.0017300065,0.0003799238,0.00035746075,0.00018909624,0.00013815521,0.0002505852,0.00005437158,0.0017118488],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9925575,0.00086843385,0.0008533816,0.00075035304,0.0039808652,0.0009894533],"domain_scores_gemma":[0.99685746,0.000694306,0.0002156665,0.0012571831,0.00064525247,0.00033014105],"candidate_categories":["sts"],"consensus_categories":[],"category_scores_codex":[0.0033288302,0.0003180884,0.0005517716,0.00026622202,0.0023866973,0.00011811674,0.00056969014,0.000118770615,0.0001938816],"category_scores_gemma":[0.0004182831,0.0001982303,0.00028598693,0.0010674404,0.00085045665,0.0001030291,0.0010426899,0.0015512871,0.000010527227],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0031476207,0.00056660385,0.041331965,0.00022864697,0.0009230342,0.0015254439,0.0026818884,0.00059090694,0.9317777,0.0005917259,0.0033517983,0.013282628],"study_design_scores_gemma":[0.003763078,0.0041089426,0.6056522,0.0006675231,0.00039467588,0.0036702936,0.0059773736,0.017750034,0.087029435,0.012521472,0.25737777,0.0010871897],"about_ca_topic_score_codex":0.0036070067,"about_ca_topic_score_gemma":0.00009527304,"teacher_disagreement_score":0.8447483,"about_ca_system_score_codex":0.000634932,"about_ca_system_score_gemma":0.0010688037,"threshold_uncertainty_score":0.99891204},"labels":[],"label_agreement":null},{"id":"W4321203706","doi":"10.1016/j.lrr.2023.100364","title":"Neuropsychiatric disorders in adults undergoing chimeric antigen receptor T cells therapy for aggressive lymphomas and acute lymphoblastic leukemia","year":2023,"lang":"en","type":"article","venue":"Leukemia Research Reports","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"","keywords":"Medicine; Cart; Chimeric antigen receptor; Lymphoblastic Leukemia; Internal medicine; Leukemia; Oncology; Immunology; Cancer; Immunotherapy","score_opus":0.02381273821878506,"score_gpt":0.3316124645774158,"score_spread":0.30779972635863073,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4321203706","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9911249,0.001330717,0.000029103598,0.0009324119,0.0005724345,0.0039441423,0.000016329584,0.00032437727,0.0017255626],"genre_scores_gemma":[0.9414383,0.048687786,0.0004145193,0.00013278914,0.00045819415,0.0008037373,0.00009636546,0.00030265396,0.007665629],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99319464,0.00042237472,0.0009011586,0.0014793363,0.002117648,0.0018848501],"domain_scores_gemma":[0.9957137,0.0017480898,0.0003402209,0.0010823996,0.0005120555,0.0006035247],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00293613,0.00045727062,0.00073768606,0.0019139397,0.000433421,0.00014848774,0.00030660714,0.00031507728,0.00031154975],"category_scores_gemma":[0.0015992653,0.0003762308,0.00025475194,0.0039739544,0.000474121,0.00021143195,0.00030331398,0.0008312848,0.00010396178],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017094195,0.0006135497,0.17024241,0.0020037612,0.0009549794,0.009938476,0.0034651235,0.00061016413,0.3433416,0.0000777638,0.035603914,0.41605407],"study_design_scores_gemma":[0.073487945,0.015217934,0.6586074,0.005280616,0.00019304422,0.004924393,0.0042771753,0.042225514,0.06135004,0.008031632,0.12269674,0.0037075365],"about_ca_topic_score_codex":0.0013012291,"about_ca_topic_score_gemma":0.00048412767,"teacher_disagreement_score":0.48836502,"about_ca_system_score_codex":0.0031892227,"about_ca_system_score_gemma":0.00578685,"threshold_uncertainty_score":0.999869},"labels":[],"label_agreement":null},{"id":"W4401434212","doi":"10.1016/j.lrr.2024.100477","title":"Successful treatment of AML using non-intensive chemotherapy in Jehovah's Witness patients","year":2024,"lang":"en","type":"article","venue":"Leukemia Research Reports","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Acute promyelocytic leukemia; Azacitidine; Arsenic trioxide; Induction chemotherapy; Myeloid leukemia; Chemotherapy; Intensive care medicine; Venetoclax; Internal medicine; Platelet transfusion; Leukemia; Blood transfusion; Retinoic acid; Oncology; Surgery; Platelet; Apoptosis","score_opus":0.05773487502074421,"score_gpt":0.3972080560227886,"score_spread":0.3394731810020444,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401434212","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99234456,0.0008285191,0.00009621962,0.00071289286,0.00028598605,0.0020388337,0.000011858382,0.00006267416,0.003618478],"genre_scores_gemma":[0.9953861,0.0006630881,0.00044488357,0.0000809554,0.00026568267,0.00015036289,0.00006961224,0.000121184734,0.002818111],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9940746,0.00021594125,0.0010001616,0.0010202993,0.0025108012,0.00117822],"domain_scores_gemma":[0.99526745,0.0004164359,0.0001380208,0.0011090764,0.0026717116,0.00039731283],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0018456955,0.00035512183,0.000861618,0.0015310494,0.00010552105,0.00008922727,0.00020290085,0.0003027428,0.00022887062],"category_scores_gemma":[0.0009726524,0.00027937154,0.00024800305,0.0023071398,0.00059468416,0.00026124163,0.00016727974,0.0008894904,0.00004880293],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0037471647,0.0019341401,0.6969869,0.0028238702,0.0010935029,0.08067595,0.0074319188,0.00033326496,0.11975891,0.00018496226,0.013050995,0.0719784],"study_design_scores_gemma":[0.023962498,0.009874519,0.32820132,0.007349478,0.0002868507,0.005479239,0.004454574,0.07795261,0.49145713,0.0028439136,0.046435222,0.0017026527],"about_ca_topic_score_codex":0.0063797315,"about_ca_topic_score_gemma":0.0001391826,"teacher_disagreement_score":0.3716982,"about_ca_system_score_codex":0.014010742,"about_ca_system_score_gemma":0.006770687,"threshold_uncertainty_score":0.99996585},"labels":[],"label_agreement":null},{"id":"W4402469124","doi":"10.1016/j.lrr.2024.100480","title":"Diagnostic challenges in classification of plasmacytoid dendritic cell proliferation associated with acute myeloid leukemia in the context of secondary-type mutations","year":2024,"lang":"en","type":"article","venue":"Leukemia Research Reports","topic":"Cutaneous lymphoproliferative disorders research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; University Health Network; University of Toronto","funders":"","keywords":"Medicine; Myeloid leukemia; Context (archaeology); Myeloid; Plasmacytoid dendritic cell; Cancer research; Immunology; Dendritic cell; Biology; Antigen","score_opus":0.06895311397010734,"score_gpt":0.356519635197072,"score_spread":0.2875665212269647,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402469124","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9869527,0.0032756133,0.00001393263,0.0013279655,0.000057192028,0.0023353703,0.000021575986,0.000033003955,0.005982639],"genre_scores_gemma":[0.99675816,0.0019128105,0.000036492234,0.000026841037,0.0000356678,0.00047370448,0.00022521231,0.000046802186,0.0004843032],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9950188,0.0007858548,0.000930873,0.0005980658,0.0021001382,0.0005662608],"domain_scores_gemma":[0.99398386,0.0036235468,0.00017809251,0.00059061113,0.0015140164,0.000109887056],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0039160545,0.00020880779,0.0004891866,0.0010828278,0.00009517323,0.00006724914,0.00019445871,0.00021530328,0.0000666854],"category_scores_gemma":[0.006469719,0.00015394973,0.0000779259,0.0021152594,0.0005021205,0.00020591085,0.000059243604,0.0012420501,0.0000109647945],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.005849527,0.0039113713,0.38136843,0.011431811,0.0016679291,0.10035511,0.1184033,0.0017340764,0.29330462,0.009172062,0.005744505,0.06705727],"study_design_scores_gemma":[0.01042276,0.0086245965,0.6634889,0.008590527,0.0004263231,0.014055988,0.06836794,0.06112498,0.15667027,0.0055316137,0.0015986229,0.0010974429],"about_ca_topic_score_codex":0.00076662475,"about_ca_topic_score_gemma":0.006485631,"teacher_disagreement_score":0.2821205,"about_ca_system_score_codex":0.00392274,"about_ca_system_score_gemma":0.010915832,"threshold_uncertainty_score":0.999901},"labels":[],"label_agreement":null},{"id":"W4405557300","doi":"10.1016/j.lrr.2024.100495","title":"Targeting menin for precision therapy in high-risk acute myeloid leukemia","year":2024,"lang":"en","type":"review","venue":"Leukemia Research Reports","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; Hamilton Health Sciences; University of Ottawa","funders":"","keywords":"Medicine; Myeloid leukemia; Cancer research; Oncology; Internal medicine","score_opus":0.08567478413901318,"score_gpt":0.43046841234776895,"score_spread":0.34479362820875575,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405557300","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0019840163,0.978291,0.00011166124,0.00023263294,0.0011058283,0.015720377,0.00026809477,0.00043000226,0.001856431],"genre_scores_gemma":[0.0002160556,0.9616476,0.0037112883,0.000056899862,0.0023087412,0.007217843,0.0019058761,0.0009071623,0.022028524],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9796811,0.0020931994,0.0043628444,0.0041119563,0.005874107,0.0038768305],"domain_scores_gemma":[0.98821497,0.0038628187,0.0011692334,0.0035105003,0.0020369086,0.0012055886],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow","research_integrity"],"category_scores_codex":[0.025497423,0.0017736277,0.00586399,0.0048057796,0.0005916358,0.00057278655,0.0013191211,0.0026092045,0.0002817061],"category_scores_gemma":[0.009100262,0.0012921147,0.0019619407,0.005278589,0.000636649,0.00039678506,0.001535329,0.012029744,0.00078938797],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00060080306,0.000108997825,0.00003963584,0.017938213,0.0014588264,0.019899858,0.00020545934,0.000015809712,0.00012026421,0.00008634095,0.16573769,0.7937881],"study_design_scores_gemma":[0.0023678401,0.0013917086,0.00001747875,0.026883759,0.0012267409,0.002936824,0.00007131266,0.0006979622,0.00014150063,0.0016999155,0.961506,0.0010589358],"about_ca_topic_score_codex":0.002402801,"about_ca_topic_score_gemma":0.000088776826,"teacher_disagreement_score":0.7957683,"about_ca_system_score_codex":0.046538178,"about_ca_system_score_gemma":0.042240992,"threshold_uncertainty_score":0.9999886},"labels":[],"label_agreement":null}]}